Published online Jun 20, 2025. doi: 10.5662/wjm.v15.i2.101430
Revised: October 17, 2024
Accepted: November 1, 2024
Published online: June 20, 2025
Processing time: 74 Days and 15.1 Hours
Microorganisms such as bacteria, fungi, viruses, parasites living in the human intestine constitute the human intestinal microbiota. Dysbiosis refers to compositional and quantitative changes that negatively affect healthy gut microbiota. In recent years, with the demonstration that many diseases are associated with dysbiosis, treatment strategies targeting the correction of dysbiosis in the treat
Core Tip: Fecal microbiota transplantation (FMT) studies have gained popularity after probiotic, prebiotic, symbiotic studies in the treatment of dysbiosis and related diseases. FMT is the process of transferring faeces from a healthy donor to another recipient in order to restore the gut microbiota and provide a therapeutic benefit.
- Citation: Tüsüz Önata E, Özdemir Ö. Fecal microbiota transplantation in allergic diseases. World J Methodol 2025; 15(2): 101430
- URL: https://www.wjgnet.com/2222-0682/full/v15/i2/101430.htm
- DOI: https://dx.doi.org/10.5662/wjm.v15.i2.101430
The community formed by microorganisms such as bacteria, fungi, viruses and parasites living in the human intestine is called intestinal microbiota. Bacteria dominate the intestinal microbiota, which is a complex ecosystem[1]. Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria are the 4 main phyla that constitute 90% of the entire bacteriome in the intestine[2]. The intestinal microbiota of an adult human consists of approximately 40 × 1012 bacteria (approximately 0.2 kg)[3]. The composition of the human gut microbiota varies from region to region (anatomical part of the gut) and is highly dynamic. Differences such as mode of delivery (normal or caesarean section), postnatal food source (breast milk, formula), various diseases, diet, age, medications used, and gender are factors affecting the microbiota[4-7]. A healthy microbiota has immunomodulatory effects (increase in the number of T helper 1 and T regulatory cells) as well as effects such as protection of intestinal integrity by preventing invasion of pathogenic bacteria, synthesis of short-chain fatty acids (SCFAs) and vitamins required for intestinal metabolism, metabolism of drugs, hormones and carcinogens[8]. Compositional and functional disruption of the microbiota affected by many genetic and host-related factors is called dysbiosis[9]. In recent years, an increasing number of diseases (such as inflammatory bowel diseases, liver diseases, diabetes, atherosclerotic diseases, neurological diseases, autoimmune diseases, allergic diseases, psychiatric disorders) have been associated with dysbiosis[10-13]. Therefore, in recent years, many studies have been conducted to investigate the effect of microbiota and correction of dysbiosis in the treatment or prevention of these diseases. Probiotic studies constitute a large part of these studies.
Probiotics reduce intestinal permeability and systemic transmission of allergens by local action. Some of the systematic effects of probiotics are (Table 1): Induction of regulatory T cell (Treg) production, deflection of the response to allergens to T helper 1 (Th1) direction, and anti-inflammatory effect by Toll- like receptor stimulation[14]. In a systematic review conducted in 2014 in which 5 randomized controlled trial (RCT) were evaluated, it was found that probiotic use had no preventive role in allergic rhinitis (AR)[15]. Likewise, in the 2019 meta-analysis including 17 RCTs, it was observed that probiotic use in the perinatal and postnatal period was not effective in the prevention of AR[16]. According to a 2020 meta-analysis including 19 RCTs, taking probiotic supplements during pregnancy or early in life did not reduce the incidence of asthma or wheeze[17]. On the other hand, a meta-analysis by Chen et al[18] showed that the use of probiotics for respiratory allergies in children improved quality of life and reduced symptom severity[18]. In a study conducted by Amalia et al[19] in 2019, it was shown that a probiotic supplement mixture given to the mother while pregnant and continuing breastfeeding, as well as to the high-risk infant, is an effective strategy to reduce the risk of atopic dermatitis (AD) in children. Current studies with probiotics are not sufficient to routinely recommend the use of probiotics in the prevention and treatment of asthma, AR and AD. This may be explained by the heterogeneity of the studies in terms of factors such as probiotic type, duration of administration and dose.
Probiotics and FMT | Potential roles |
Probiotics | Epithelial integrity ↑ |
Tight junction protein expression ↑ | |
Bacterial translocation ↓ | |
Inflammatory cytokines such as IL-6, IL-8 and TNF-α ↓ | |
Restoration of Th1/Th2 balance | |
Treg cell numbers and function, IL-10 and TGF-β ↑ | |
SCFAs production (especially butyrate) ↑ | |
FMT | Pro-inflammatory cytokine secretion ↓ |
Restoration of Th1/Th2 balance | |
Stimulates T cell activity and leukocyte adhesion | |
Change in intestinal bacterial diversity (Firmicutes, Bacteroidetes ↑/Proteobacteria, Actinobacteria ↓) | |
Intestinal permeability ↓ | |
Epithelial integrity ↑ | |
SCFAs production ↑ | |
Intestinal pH ↓ | |
Bacterial adhesion to H2O2 ↑ |
On the other hand, FMT is thought to be more effective than probiotics in the restoration of altered intestinal microbiota. The reasons for this are that the number and diversity of microorganisms provided by FMT is higher than that provided by probiotics, and while there is a permanent change in the recipient microbiota after FMT, probiotics can colonize the intestinal lumen only temporarily[20-22]. In this article, FMT which is promising in the treatment of allergic diseases and the effect of FMT in allergic diseases will be discussed.
Faecal microbiota transplantation (FMT) is the process of transferring faeces from a healthy donor into the gastrointestinal tract of the recipient in order to repair the intestinal microbiota and provide a therapeutic benefit[23]. The first FMT application was performed in China and dates back to 300-400 AD. The first applications were recorded as oral administration of human faecal suspension to patients with food poisoning or severe diarrhoea[24]. The first introduction of FMT into the medical literature was in 1958 reported FMT administered via enema as a highly effective treatment in the treatment of severe pseudomembranous enterocolitis[25]. In 2013, in a randomized controlled trial conducted by van Nood et al[26], FMT was found to be 81% successful in the treatment of recurrent C. difficile (rCDI) infection compared to 31% with standard antibiotic treatment and the Food and Drug Administration (FDA) approved the use of FMT in humans in the same year[26,27]. This significant success of FMT in the treatment of rCDI has created great excitement for its use in the treatment of other diseases associated with dysbiosis.
The main objective is to rebuild the gut microbiota by normalizing immune and inflammatory responses, the amount and activity of neurotransmitters/vasoactive substances and intestinal energy metabolism. This main objective is realized through the following mechanisms (Table 1): (1) The main goal of FMT is to restore the “normal” bacterial population in a dysbiotic colonic environment[25]; (2) A change in the bacterial population in the intestine occurs that mirrors the donor feces[25]; (3) An increase in Firmicutes and Bacteroidetes and a decrease in Proteobacteria and Actinobacteria[25]; (4) It may reduce intestinal permeability and maintain the integrity of the epithelial barrier by increasing the production of SCFAs[23]; (5) It inhibits the secretion of proinflammatory cytokines[23]; (6) It promotes Th1 cell differentiation, T cell activity, leukocyte adhesion and immunostimulating factors[23]; and (7) It lowers intestinal pH and inhibits the transport of pathogenic microorganisms by increasing bacterial adhesion to H2O2[23].
There is no standard protocol for the preparation of FMT. The recommended and commonly used method of FMT preparation for rCDI is as follows: 50-60 g of faeces and 200-300 mL of diluent (water, saline or milk) are homogenized and suspended. The suspension is left to settle for 5 minutes. Then it is passed through gauze and then through a syringe with filter. The resulting filtrate is ready for FMT[28]. There are routes of administration of FMT such as oral administration in the form of capsules, nasal administration, administration into the upper gastrointestinal tract with the help of nasogastric or nasoduodenal tube, rectal administration via colonoscopy or enema[29].
Although FMT is generally considered safe, the adverse event rate was reported as 28.5% in a systematic review. However, most of these side effects were self-limiting and included abdominal pain, gas, increased stool frequency, vomiting and fever. Serious adverse events were more rare and occurred in 5%. Although more serious side effects such as aspiration and intestinal perforation have been reported after FMT, these risks are mostly related to the route of administration[30]. Administration of FMT via capsules is a less invasive approach and can be used to overcome complications related with the route of administration[31,32]. FMT also has reported side effects including sepsis, peritonitis and toxic megacolon[30]. To prevent disease transmission from donor to recipient, it should be ensured that the donor is completely healthy. The donor is examined for the presence of human immunodeficiency virus, syphilis, hepatitis A, B, C, autoimmune and atopic diseases. The donor's faecal material is also examined for the presence of parasites, helminth eggs and pathogenic bacterial toxins. The donor should be free of tumors, inflammation, diabetes, infectious diseases and metabolic syndrome and the donor should not be obese. In addition, the donor should not be using immunosuppressants, steroids, probiotics, aspirin, proton pump inhibitors and antibiotics[33]. FDA has recently recommended additional donor screening and testing protocols to reduce the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and monkeypox transmission with FMT[34].
As mentioned above, FMT is a method applied to restore the gut microbiota and provide a therapeutic benefit and dates back to 300-400 AD and China[23]. The first clinical applications were oral administration of human fecal suspension to patients with food poisoning or severe diarrhea[24]. Studies conducted in the last decade have demonstrated the potential efficacy of FMT in conditions such as ulcerative colitis (UC), Crohn's disease, epilepsy, autism and recurrent urinary tract infections (UTIs)[20-24].
FMT has also been proven to be highly effective in the treatment of rCDI (approximately 90% cure rate) and FMT has become an undisputed treatment modality for rCDI[35,36]. A recent systematic review revealed that FMT can treat 85 specific diseases. When evaluated according to the number of cases treated using FMT, the diseases such as intestinal infections (rDCI), UC, irritable bowel syndrome, constipation, hypertension, fatty liver disease, autism spectrum disorders, radiation enteritis are the leading diseases[35]. In addition to these diseases, FMT has also been found to be effective in diseases such as hepatic encephalopathy, epilepsy, depression, metabolic syndrome, obesity, primary sclerosing cholangitis, anorexia and recurrent UTI[37-45]. Various animal studies and human case reports for Parkinson's disease, Alzheimer's disease, multiple sclerosis and stroke show the positive effect of FMT in these diseases[46-50].
The increase in the prevalence of allergic diseases in modern societies over the last 50-60 years is remarkable. This allergy pandemic is explained by 2 hypotheses: Hygiene hypothesis[51] and microbiota hypothesis[52]. T helper 2 (Th 2) response is dominant in humans during pregnancy and the first years of life[53]. Microbial agents encountered in the early period of life cause interleukin (IL) 12 production from macrophages, the innate cells of the immune system. IL-12 plays a key role in the progression of the immune system towards Th 1. According to the hygiene hypothesis, if IL-12 production does not occur in the early stages of childhood, Th 2 cells will predominate and as a result, atopy will develop in genetically predisposed children[54]. A healthy gut microbiota helps to maintain intestinal integrity by preventing the invasion of pathogenic bacteria and to prevent the development of allergies through immunomodulatory effects (increase in the number of Th 1 and Treg cells)[8]. Today, factors such as excessive use of antibiotics, consumption of more germ-free foods, better personal hygiene, and smaller family size are held responsible for changes in intestinal microbiota and allergy risk[55-57]. Many studies have shown that traditional agriculture has a preventive effect on the prevalence and incidence of asthma in childhood; exposure to farm animals and their feed and consumption of unpasteurized cow's milk have a protective effect on asthma. Higher microbial exposure is hypothesized to have a protective effect on allergy development[58,59]. Decreased microbiotal diversity in the gastrointestinal tract has been found to be associated with diseases such as atopy, asthma and eczema[60-63]. For all these reasons, the effect of FMT in allergic diseases has started to be investigated more recently (Table 2). In the following sections of this article, the use of FMT in allergic diseases will be emphasized.
Disease | Species | Main result | Ref. |
Food allergy | Mice | Food allergy protection was achieved in food allergy-prone recipient mice receiving FMT from a healthy donor | [69] |
Mice | It has been shown that recipient germ-free mice after FMT from healthy and cow's milk allergy-free donors are protected against anaphylactic reactions to cow's milk allergen | [70] | |
Human | Phase 1 and phase 2 study investigating the efficacy of oral capsule FMT in people with peanut allergy is ongoing | [71,72] | |
Eosinophilic gastritis | Human | Combination of FMT and steroid therapy in a patient with steroid-resistant eosinophilic gastritis improved the patient's symptoms | [76] |
Allergic proctocolitis (FPIAP) | Human | After 2 days after administration of FMT via rectal tube to 19 infants with FPIAP, 17 infants showed symptomatic regression | [80] |
Atopic dermatitis | Mice | In recipient mice after FMT administered from non-atopic dermatitis patients to atopic dermatitis patients: SCFA ↑, Th1 cytokines (IL-12, IFN-γ, TNF-α) ↑, Th2 cytokines (IL-4, IL-5, IL-13) ↓, Total IgE ↓, SCORAD ↓ | [86,87] |
Human | After FMT in patients with moderate to severe AD: SCORAD ↓, need for topical corticosteroids ↓ | [88] | |
Allergic rhinitis | Mice | In recipient mice after FMT: nasal symptoms ↓, Total IgE ↓, histopathological recovery (decrease in eosinophilia) | [91] |
Low microbial diversity in the intestines and high Enterobacteriaceae/Bacteroidaceae ratio have been associated with the development of food sensitivity in children[64]. Similarly, the risk of allergic diseases was found to be higher in children born after caesarean section who did not receive vaginal microbiota from their mothers[65]. In the absence of healthy microbiota, the decrease in SCFA, which are also involved in the recovery of epithelial barrier integrity, will lead to increased sensitivity to food allergens[66,67]. The first studies with germ-free mice showed the importance of gut microbiota in modulating food allergy and revealed that germ-free mice could not develop tolerance against food allergens[68]. Recent studies with germ-free mice demonstrated the importance of gut microbiota in modulating food allergy and revealed that germ-free mice without healthy gut microbiota could not develop tolerance to food allergens[69,70]. These findings obtained with FMT in mouse models have formed the basis of new studies to be conducted in humans. A Phase 1 study with 10 adult subjects to monitor the safety and tolerability of oral capsule FMT administered for 2 days in the treatment of peanut allergy has been completed but the data have not yet been published[71]. A phase II randomized double-blind placebo-controlled phase II randomized double-blind placebo-controlled study to evaluate the safety and tolerability of oral encapsulated FMT in 24 patients with peanut allergy is still ongoing[72].
Eosinophilic gastrointestinal disorders are a group of rare disorders characterized by pathological eosinophilic infiltration of the gastrointestinal tract with symptoms such as dysphagia, abdominal pain, nausea, vomiting, early satiety, diarrhoea and weight loss. These Th 2 -mediated disorders include eosinophilic oesophagitis, eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), eosinophilic enteritis (EE) and eosinophilic colitis. Symptoms of the disease vary according to the site of involvement and depth of involvement (mucosa, submucosa, serosa)[73-75]. Although there is no consensus on the treatment of EGE so far, steroid treatment forms the basis of treatment. In the literature, there is a case report in which the combination of FMT and steroid treatment improved the symptoms of a 35-year-old patient with EG who did not respond to steroid treatment alone[76].
Allergic colitis, also known as food protein-induced allergic proctocolitis (FPIAP), is a clinical entity characterized by inflammatory changes developing in the distal colon in response to one or more food proteins. Although the underlying mechanism in allergic colitis is not known, IgE is thought not to play a role[77]. Symptoms in infants with FPIAP usually start in the first months of life. Patients present with red blood and mucus mixed with stools with or without diarrhoea[78]. The most common trigger for FPIAP is cow's milk and elimination diet, which involves the removal of the responsible food from the diet, is the mainstay of treatment of allergic enteritis[79]. In a 2017 study, 19 infants with proctocolitis who had severe diarrhoea/haematochezia and who did not recover completely with routine treatment were treated with FMT via rectal tube and clinical results were followed up. In 17 infants, allergic colitis symptoms were alleviated within 2 days after FMT and no recurrence was observed during the following 15 months. According to 16S rDNA analysis performed in 10 of these babies, an increase in microbiota diversity was observed in most of these babies after FMT[80].
AD (eczema) is a condition that causes dry, itchy and inflamed skin. Atopic dermatitis is one of the chronic inflammatory skin diseases affecting 15%-30% of children and 10% of adults in which impaired barrier function, immune response and microbial factors play a role in its pathogenesis[81,82]. In recent years, as in many diseases, the treatment of AD has focused on gut microbiota in relation to immune modulation. Different results have been reported in various studies investigating the effects of probiotic treatment on AD and the efficacy of probiotics in AD treatment has not been proven[83-85]. In recent years, studies on the effects of FMT in the treatment of AD have started to be carried out because of the reconstitution of the intestinal microbiota and the long-term change of the recipient microbiome. In a study conducted with mice with and without AD, an increase in SCFA levels was found in recipient mice after FMT. As a result of the measurement of cytokine levels before and after FMT in mice with AD, Th-2 cytokines (IL-4, IL-5, IL-13) decreased and Th1 cytokines (IL-12, IFN-γ and TNF-α) increased, total IgE level decreased and dermatitis scores decreased after FMT[86]. Similar results were found in another mouse study conducted in 2023[87]. In a human study conducted with 9 patients with moderate to severe AD, a significant improvement in AD SCORAD (SCORing Atopic Dermatitis) scores and a decrease in the frequency of weekly topical corticosteroid use were observed in 7 patients after FMT. No side effects were reported during the study[88]. These studies show that FMT may be effective through immune modulation by gut microbiota and are promising for the future of AD treatment, but more clinical studies are needed.
AR is an IgE-mediated inflammatory disease of the upper airway induced by inhaled allergens affecting 10-30% of the world population[89,90]. In an experimental mouse model investigating the effect of FMT on AR, it was found that nasal symptoms were significantly alleviated in recipient mice after transplantation of normal mouse faecal microbiota into AR mice. In contrast, it was observed that AR symptoms developed in healthy mice that received FMT from allergic mice. In the study, it was found that total IgE levels decreased in AR mice treated with FMT. In addition, histopathological evaluation of the nasal mucosa was performed after FMT and a decrease in eosinophil levels was observed in the reci
Asthma is one of the most common chronic diseases thought to affect more than 300 million people worldwide[93]. Asthma is related with the predominance of the immune response in the Th2 direction and its etiology has not yet been fully elucidated. Genetic and environmental factors are also thought to contribute to the pathogenesis of asthma[94,95]. Intestinal microbial triggers are an important environmental factor associated with asthma. Recent studies have shown that gut microbiota plays a role in the etiology of asthma through its effects on innate and adaptive immunity[96,97]. In line with this information, FMT represents a possible treatment modality to improve asthma. However, scientific studies in this field have only recently begun[98].
After the high success rate of FMT, especially in the treatment of rCDI, and the increase in data proving the relationship between disorders in the intestinal microbiota and many diseases in recent years, the number of studies investigating the effects of FMT in these diseases has increased. Until this time, studies targeting microbiota in disease treatment have mostly been probiotic studies. The most important limitation of probiotic treatment in the treatment of diseases is that the variety of microorganisms given in probiotic treatment is limited and the duration of action is short. FMT is thought to be more successful in the treatment of diseases because it contains more and various microorganisms and can provide a more permanent microbial environment. Studies on the efficacy of FMT in the treatment of allergic diseases have only recently started and the first results are promising for the use of FMT in the treatment of allergic diseases in the future. However, more clinical studies are needed to recommend the routine use of FMT in the treatment of diseases.
1. | Ursell LK, Metcalf JL, Parfrey LW, Knight R. Defining the human microbiome. Nutr Rev. 2012;70 Suppl 1:S38-S44. [PubMed] [DOI] [Cited in This Article: ] |
2. | Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S, Doré J; MetaHIT Consortium, Antolín M, Artiguenave F, Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariaz G, Dervyn R, Foerstner KU, Friss C, van de Guchte M, Guedon E, Haimet F, Huber W, van Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, Lakhdari O, Layec S, Le Roux K, Maguin E, Mérieux A, Melo Minardi R, M'rini C, Muller J, Oozeer R, Parkhill J, Renault P, Rescigno M, Sanchez N, Sunagawa S, Torrejon A, Turner K, Vandemeulebrouck G, Varela E, Winogradsky Y, Zeller G, Weissenbach J, Ehrlich SD, Bork P. Enterotypes of the human gut microbiome. Nature. 2011;473:174-180. [PubMed] [DOI] [Cited in This Article: ] |
3. | Sender R, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 2016;14:e1002533. [PubMed] [DOI] [Cited in This Article: ] |
4. | Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol. 2015;21:8787-8803. [PubMed] [DOI] [Cited in This Article: ] |
5. | Martinez-Guryn K, Leone V, Chang EB. Regional Diversity of the Gastrointestinal Microbiome. Cell Host Microbe. 2019;26:314-324. [PubMed] [DOI] [Cited in This Article: ] |
6. | Rodríguez JM, Murphy K, Stanton C, Ross RP, Kober OI, Juge N, Avershina E, Rudi K, Narbad A, Jenmalm MC, Marchesi JR, Collado MC. The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis. 2015;26:26050. [PubMed] [DOI] [Cited in This Article: ] |
7. | Vemuri R, Sylvia KE, Klein SL, Forster SC, Plebanski M, Eri R, Flanagan KL. The microgenderome revealed: sex differences in bidirectional interactions between the microbiota, hormones, immunity and disease susceptibility. Semin Immunopathol. 2019;41:265-275. [PubMed] [DOI] [Cited in This Article: ] |
8. | Ozdemir O. Prebiotics and Probiotics in Allergy: Potential Mechanisms of Prebiotics’ and Probiotics’ Actions in Allergy - (Part 1). MOJ Immunol. 2016;3. [DOI] [Cited in This Article: ] |
9. | Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, Costea PI, Godneva A, Kalka IN, Bar N, Shilo S, Lador D, Vila AV, Zmora N, Pevsner-Fischer M, Israeli D, Kosower N, Malka G, Wolf BC, Avnit-Sagi T, Lotan-Pompan M, Weinberger A, Halpern Z, Carmi S, Fu J, Wijmenga C, Zhernakova A, Elinav E, Segal E. Environment dominates over host genetics in shaping human gut microbiota. Nature. 2018;555:210-215. [PubMed] [DOI] [Cited in This Article: ] |
10. | Albhaisi SAM, Bajaj JS, Sanyal AJ. Role of gut microbiota in liver disease. Am J Physiol Gastrointest Liver Physiol. 2020;318:G84-G98. [PubMed] [DOI] [Cited in This Article: ] |
11. | Gomaa EZ. Human gut microbiota/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek. 2020;113:2019-2040. [PubMed] [DOI] [Cited in This Article: ] |
12. | Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol. 2015;3:207-215. [PubMed] [DOI] [Cited in This Article: ] |
13. | Palacios T, Vitetta L, Coulson S, Madigan CD, Denyer GS, Caterson ID. The effect of a novel probiotic on metabolic biomarkers in adults with prediabetes and recently diagnosed type 2 diabetes mellitus: study protocol for a randomized controlled trial. Trials. 2017;18:7. [PubMed] [DOI] [Cited in This Article: ] |
14. | Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis. 2009;15:300-310. [PubMed] [DOI] [Cited in This Article: ] |
15. | Peng Y, Li A, Yu L, Qin G. The role of probiotics in prevention and treatment for patients with allergic rhinitis: A systematic review. Am J Rhinol Allergy. 2015;29:292-298. [PubMed] [DOI] [Cited in This Article: ] |
16. | Du X, Wang L, Wu S, Yuan L, Tang S, Xiang Y, Qu X, Liu H, Qin X, Liu C. Efficacy of probiotic supplementary therapy for asthma, allergic rhinitis, and wheeze: a meta-analysis of randomized controlled trials. Allergy Asthma Proc. 2019;40:250-260. [PubMed] [DOI] [Cited in This Article: ] |
17. | Wei X, Jiang P, Liu J, Sun R, Zhu L. Association between probiotic supplementation and asthma incidence in infants: a meta-analysis of randomized controlled trials. J Asthma. 2020;57:167-178. [PubMed] [DOI] [Cited in This Article: ] |
18. | Chen N, Liu F, Gao Q, Wang R, Zhang L, Li Y. A Meta-Analysis of Probiotics for the Treatment of Allergic Airway Diseases in Children and Adolescents. Am J Rhinol Allergy. 2022;36:480-490. [PubMed] [DOI] [Cited in This Article: ] |
19. | Amalia N, Orchard D, Francis KL, King E. Systematic review and meta-analysis on the use of probiotic supplementation in pregnant mother, breastfeeding mother and infant for the prevention of atopic dermatitis in children. Australas J Dermatol. 2020;61:e158-e173. [PubMed] [DOI] [Cited in This Article: ] |
20. | Grehan MJ, Borody TJ, Leis SM, Campbell J, Mitchell H, Wettstein A. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol. 2010;44:551-561. [PubMed] [DOI] [Cited in This Article: ] |
21. | Tannock GW, Munro K, Harmsen HJ, Welling GW, Smart J, Gopal PK. Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Appl Environ Microbiol. 2000;66:2578-2588. [PubMed] [DOI] [Cited in This Article: ] |
22. | Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2010;44:354-360. [PubMed] [DOI] [Cited in This Article: ] |
23. | Gu X, Chen ZH, Zhang SC. Fecal microbiota transplantation in childhood: past, present, and future. World J Pediatr. 2023;19:813-822. [PubMed] [DOI] [Cited in This Article: ] |
24. | Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol. 2012;107:1755; author reply p.1755-1755; author reply p.1756. [PubMed] [DOI] [Cited in This Article: ] |
25. | Vindigni SM, Surawicz CM. Fecal Microbiota Transplantation. Gastroenterol Clin North Am. 2017;46:171-185. [PubMed] [DOI] [Cited in This Article: ] |
26. | van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407-415. [PubMed] [DOI] [Cited in This Article: ] |
27. | Wang JW, Kuo CH, Kuo FC, Wang YK, Hsu WH, Yu FJ, Hu HM, Hsu PI, Wang JY, Wu DC. Fecal microbiota transplantation: Review and update. J Formos Med Assoc. 2019;118 Suppl 1:S23-S31. [PubMed] [DOI] [Cited in This Article: ] |
28. | Perez E, Lee CH, Petrof EO. A Practical Method for Preparation of Fecal Microbiota Transplantation. Methods Mol Biol. 2016;1476:259-267. [PubMed] [DOI] [Cited in This Article: ] |
29. | Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc. 2013;78:240-249. [PubMed] [DOI] [Cited in This Article: ] |
30. | Wang S, Xu M, Wang W, Cao X, Piao M, Khan S, Yan F, Cao H, Wang B. Systematic Review: Adverse Events of Fecal Microbiota Transplantation. PLoS One. 2016;11:e0161174. [PubMed] [DOI] [Cited in This Article: ] |
31. | Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, Chang HJ, Coward S, Goodman KJ, Xu H, Madsen K, Mason A, Wong GK, Jovel J, Patterson J, Louie T. Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA. 2017;318:1985-1993. [PubMed] [DOI] [Cited in This Article: ] |
32. | Vaughn BP, Fischer M, Kelly CR, Allegretti JR, Graiziger C, Thomas J, McClure E, Kabage AJ, Khoruts A. Effectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Clin Gastroenterol Hepatol. 2023;21:1330-1337.e2. [PubMed] [DOI] [Cited in This Article: ] |
33. | Ng RW, Dharmaratne P, Wong S, Hawkey P, Chan P, Ip M. Revisiting the donor screening protocol of faecal microbiota transplantation (FMT): a systematic review. Gut. 2024;73:1029-1031. [PubMed] [DOI] [Cited in This Article: ] |
34. | Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology. 2020;158:1518-1519. [PubMed] [DOI] [Cited in This Article: ] |
35. | Wang Y, Zhang S, Borody TJ, Zhang F. Encyclopedia of fecal microbiota transplantation: a review of effectiveness in the treatment of 85 diseases. Chin Med J (Engl). 2022;135:1927-1939. [PubMed] [DOI] [Cited in This Article: ] |
36. | Quraishi MN, Widlak M, Bhala N, Moore D, Price M, Sharma N, Iqbal TH. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017;46:479-493. [PubMed] [DOI] [Cited in This Article: ] |
37. | Ahluwalia V, Betrapally NS, Hylemon PB, White MB, Gillevet PM, Unser AB, Fagan A, Daita K, Heuman DM, Zhou H, Sikaroodi M, Bajaj JS. Impaired Gut-Liver-Brain Axis in Patients with Cirrhosis. Sci Rep. 2016;6:26800. [PubMed] [DOI] [Cited in This Article: ] |
38. | He Z, Cui BT, Zhang T, Li P, Long CY, Ji GZ, Zhang FM. Fecal microbiota transplantation cured epilepsy in a case with Crohn's disease: The first report. World J Gastroenterol. 2017;23:3565-3568. [PubMed] [DOI] [Cited in This Article: ] |
39. | Cai T, Shi X, Yuan LZ, Tang D, Wang F. Fecal microbiota transplantation in an elderly patient with mental depression. Int Psychogeriatr. 2019;31:1525-1526. [PubMed] [DOI] [Cited in This Article: ] |
40. | Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143:913-6.e7. [PubMed] [DOI] [Cited in This Article: ] |
41. | Tap J, Ruppé E, Derrien M. The Human Gut Microbiota in all its States: From Disturbance to Resilience. Compr Gut Microbiota. 2022;. [DOI] [Cited in This Article: ] |
42. | Kootte RS, Levin E, Salojärvi J, Smits LP, Hartstra AV, Udayappan SD, Hermes G, Bouter KE, Koopen AM, Holst JJ, Knop FK, Blaak EE, Zhao J, Smidt H, Harms AC, Hankemeijer T, Bergman JJGHM, Romijn HA, Schaap FG, Olde Damink SWM, Ackermans MT, Dallinga-Thie GM, Zoetendal E, de Vos WM, Serlie MJ, Stroes ESG, Groen AK, Nieuwdorp M. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metab. 2017;26:611-619.e6. [PubMed] [DOI] [Cited in This Article: ] |
43. | Allegretti JR, Kassam Z, Carrellas M, Mullish BH, Marchesi JR, Pechlivanis A, Smith M, Gerardin Y, Timberlake S, Pratt DS, Korzenik JR. Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial. Am J Gastroenterol. 2019;114:1071-1079. [PubMed] [DOI] [Cited in This Article: ] |
44. | de Clercq NC, Frissen MN, Davids M, Groen AK, Nieuwdorp M. Weight Gain after Fecal Microbiota Transplantation in a Patient with Recurrent Underweight following Clinical Recovery from Anorexia Nervosa. Psychother Psychosom. 2019;88:58-60. [PubMed] [DOI] [Cited in This Article: ] |
45. | Biehl LM, Cruz Aguilar R, Farowski F, Hahn W, Nowag A, Wisplinghoff H, Vehreschild MJGT. Fecal microbiota transplantation in a kidney transplant recipient with recurrent urinary tract infection. Infection. 2018;46:871-874. [PubMed] [DOI] [Cited in This Article: ] |
46. | Cui B, Su D, Li W, She X, Zhang M, Wang R, Zhai Q. Effects of chronic noise exposure on the microbiome-gut-brain axis in senescence-accelerated prone mice: implications for Alzheimer's disease. J Neuroinflammation. 2018;15:190. [PubMed] [DOI] [Cited in This Article: ] |
47. | Spychala MS, Venna VR, Jandzinski M, Doran SJ, Durgan DJ, Ganesh BP, Ajami NJ, Putluri N, Graf J, Bryan RM, McCullough LD. Age-related changes in the gut microbiota influence systemic inflammation and stroke outcome. Ann Neurol. 2018;84:23-36. [PubMed] [DOI] [Cited in This Article: ] |
48. | Zhou ZL, Jia XB, Sun MF, Zhu YL, Qiao CM, Zhang BP, Zhao LP, Yang Q, Cui C, Chen X, Shen YQ. Neuroprotection of Fasting Mimicking Diet on MPTP-Induced Parkinson's Disease Mice via Gut Microbiota and Metabolites. Neurotherapeutics. 2019;16:741-760. [PubMed] [DOI] [Cited in This Article: ] |
49. | Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner R, Bencosme Y, Lee YK, Hauser SL, Crabtree-Hartman E, Sand IK, Gacias M, Zhu Y, Casaccia P, Cree BAC, Knight R, Mazmanian SK, Baranzini SE. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A. 2017;114:10713-10718. [PubMed] [DOI] [Cited in This Article: ] |
50. | Makkawi S, Camara-Lemarroy C, Metz L. Fecal microbiota transplantation associated with 10 years of stability in a patient with SPMS. Neurol Neuroimmunol Neuroinflamm. 2018;5:e459. [PubMed] [DOI] [Cited in This Article: ] |
51. | Cabana MD, McKean M, Wong AR, Chao C, Caughey AB. Examining the hygiene hypothesis: the Trial of Infant Probiotic Supplementation. Paediatr Perinat Epidemiol. 2007;21 Suppl 3:23-28. [PubMed] [DOI] [Cited in This Article: ] |
52. | Noverr MC, Huffnagle GB. The 'microflora hypothesis' of allergic diseases. Clin Exp Allergy. 2005;35:1511-1520. [PubMed] [DOI] [Cited in This Article: ] |
53. | Kalliomäki M, Isolauri E. Pandemic of atopic diseases--a lack of microbial exposure in early infancy? Curr Drug Targets Infect Disord. 2002;2:193-199. [PubMed] [DOI] [Cited in This Article: ] |
54. | Hertzen LC. The hygiene hypothesis in the development of atopy and asthma--still a matter of controversy? QJM. 1998;91:767-771. [PubMed] [DOI] [Cited in This Article: ] |
55. | von Mutius E. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: farm lifestyles and the hygiene hypothesis. Clin Exp Immunol. 2010;160:130-135. [PubMed] [DOI] [Cited in This Article: ] |
56. | West CE, Renz H, Jenmalm MC, Kozyrskyj AL, Allen KJ, Vuillermin P, Prescott SL; in-FLAME Microbiome Interest Group. The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies. J Allergy Clin Immunol. 2015;135:3-13; quiz 14. [PubMed] [DOI] [Cited in This Article: ] |
57. | Melli LC, do Carmo-Rodrigues MS, Araújo-Filho HB, Solé D, de Morais MB. Intestinal microbiota and allergic diseases: A systematic review. Allergol Immunopathol (Madr). 2016;44:177-188. [PubMed] [DOI] [Cited in This Article: ] |
58. | Pechlivanis S, von Mutius E. Effect of Farming on Asthma. Acta Med Acad. 2020;49:144-155. [PubMed] [DOI] [Cited in This Article: ] |
59. | Ege MJ, Bieli C, Frei R, van Strien RT, Riedler J, Ublagger E, Schram-Bijkerk D, Brunekreef B, van Hage M, Scheynius A, Pershagen G, Benz MR, Lauener R, von Mutius E, Braun-Fahrländer C; Parsifal Study team. Prenatal farm exposure is related to the expression of receptors of the innate immunity and to atopic sensitization in school-age children. J Allergy Clin Immunol. 2006;117:817-823. [PubMed] [DOI] [Cited in This Article: ] |
60. | Bisgaard H, Li N, Bonnelykke K, Chawes BL, Skov T, Paludan-Müller G, Stokholm J, Smith B, Krogfelt KA. Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. J Allergy Clin Immunol. 2011;128:646-52.e1. [PubMed] [DOI] [Cited in This Article: ] |
61. | Penders J, Gerhold K, Stobberingh EE, Thijs C, Zimmermann K, Lau S, Hamelmann E. Establishment of the intestinal microbiota and its role for atopic dermatitis in early childhood. J Allergy Clin Immunol. 2013;132:601-607.e8. [PubMed] [DOI] [Cited in This Article: ] |
62. | van Nimwegen FA, Penders J, Stobberingh EE, Postma DS, Koppelman GH, Kerkhof M, Reijmerink NE, Dompeling E, van den Brandt PA, Ferreira I, Mommers M, Thijs C. Mode and place of delivery, gastrointestinal microbiota, and their influence on asthma and atopy. J Allergy Clin Immunol. 2011;128:948-55.e1. [PubMed] [DOI] [Cited in This Article: ] |
63. | Abrahamsson TR, Jakobsson HE, Andersson AF, Björkstén B, Engstrand L, Jenmalm MC. Low gut microbiota diversity in early infancy precedes asthma at school age. Clin Exp Allergy. 2014;44:842-850. [PubMed] [DOI] [Cited in This Article: ] |
64. | Azad MB, Konya T, Guttman DS, Field CJ, Sears MR, HayGlass KT, Mandhane PJ, Turvey SE, Subbarao P, Becker AB, Scott JA, Kozyrskyj AL; CHILD Study Investigators. Infant gut microbiota and food sensitization: associations in the first year of life. Clin Exp Allergy. 2015;45:632-643. [PubMed] [DOI] [Cited in This Article: ] |
65. | Lee E, Kim BJ, Kang MJ, Choi KY, Cho HJ, Kim Y, Yang SI, Jung YH, Kim HY, Seo JH, Kwon JW, Kim HB, Lee SY, Hong SJ. Dynamics of Gut Microbiota According to the Delivery Mode in Healthy Korean Infants. Allergy Asthma Immunol Res. 2016;8:471-477. [PubMed] [DOI] [Cited in This Article: ] |
66. | Roduit C, Frei R, Ferstl R, Loeliger S, Westermann P, Rhyner C, Schiavi E, Barcik W, Rodriguez-Perez N, Wawrzyniak M, Chassard C, Lacroix C, Schmausser-Hechfellner E, Depner M, von Mutius E, Braun-Fahrländer C, Karvonen AM, Kirjavainen PV, Pekkanen J, Dalphin JC, Riedler J, Akdis C, Lauener R, O'Mahony L; PASTURE/EFRAIM study group. High levels of butyrate and propionate in early life are associated with protection against atopy. Allergy. 2019;74:799-809. [PubMed] [DOI] [Cited in This Article: ] |
67. | Tan JK, Macia L, Mackay CR. Dietary fiber and SCFAs in the regulation of mucosal immunity. J Allergy Clin Immunol. 2023;151:361-370. [PubMed] [DOI] [Cited in This Article: ] |
68. | Sudo N, Sawamura S, Tanaka K, Aiba Y, Kubo C, Koga Y. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. J Immunol. 1997;159:1739-1745. [PubMed] [Cited in This Article: ] |
69. | Sokal G, Michaux JL, Van Den Berghe H. [Refractory anemia and chromosome 5 q -: a new syndrome]. Bull Mem Acad R Med Belg. 1975;130:368-386. [PubMed] [DOI] [Cited in This Article: ] |
70. | Feehley T, Plunkett CH, Bao R, Choi Hong SM, Culleen E, Belda-Ferre P, Campbell E, Aitoro R, Nocerino R, Paparo L, Andrade J, Antonopoulos DA, Berni Canani R, Nagler CR. Healthy infants harbor intestinal bacteria that protect against food allergy. Nat Med. 2019;25:448-453. [PubMed] [DOI] [Cited in This Article: ] |
71. | Ezhuthachan ID, Beaudoin M, Nowak-Wegrzyn A, Vickery BP. The Future of Food Allergy Management: Advancements in Therapies. Curr Allergy Asthma Rep. 2024;24:161-171. [PubMed] [DOI] [Cited in This Article: ] |
72. | Jensen C, Antonsen MF, Lied GA. Gut Microbiota and Fecal Microbiota Transplantation in Patients with Food Allergies: A Systematic Review. Microorganisms. 2022;10. [PubMed] [DOI] [Cited in This Article: ] |
73. | Spergel JM, Book WM, Mays E, Song L, Shah SS, Talley NJ, Bonis PA. Variation in prevalence, diagnostic criteria, and initial management options for eosinophilic gastrointestinal diseases in the United States. J Pediatr Gastroenterol Nutr. 2011;52:300-306. [PubMed] [DOI] [Cited in This Article: ] |
74. | Zhang L, Duan L, Ding S, Lu J, Jin Z, Cui R, McNutt M, Wang A. Eosinophilic gastroenteritis: clinical manifestations and morphological characteristics, a retrospective study of 42 patients. Scand J Gastroenterol. 2011;46:1074-1080. [PubMed] [DOI] [Cited in This Article: ] |
75. | Kinoshita Y, Ishihara S. Eosinophilic gastroenteritis: epidemiology, diagnosis, and treatment. Curr Opin Allergy Clin Immunol. 2020;20:311-315. [PubMed] [DOI] [Cited in This Article: ] |
76. | Dai YX, Shi CB, Cui BT, Wang M, Ji GZ, Zhang FM. Fecal microbiota transplantation and prednisone for severe eosinophilic gastroenteritis. World J Gastroenterol. 2014;20:16368-16371. [PubMed] [DOI] [Cited in This Article: ] |
77. | Boné J, Claver A, Guallar I, Plaza AM. Allergic proctocolitis, food-induced enterocolitis: immune mechanisms, diagnosis and treatment. Allergol Immunopathol (Madr). 2009;37:36-42. [PubMed] [DOI] [Cited in This Article: ] |
78. | Lozinsky AC, Morais MB. Eosinophilic colitis in infants. J Pediatr (Rio J). 2014;90:16-21. [PubMed] [DOI] [Cited in This Article: ] |
79. | Czerwionka-Szaflarska M, Łoś-Rycharska E, Gawryjołek J. Allergic enteritis in children. Prz Gastroenterol. 2017;12:1-5. [PubMed] [DOI] [Cited in This Article: ] |
80. | Liu SX, Li YH, Dai WK, Li XS, Qiu CZ, Ruan ML, Zou B, Dong C, Liu YH, He JY, Huang ZH, Shu SN. Fecal microbiota transplantation induces remission of infantile allergic colitis through gut microbiota re-establishment. World J Gastroenterol. 2017;23:8570-8581. [PubMed] [DOI] [Cited in This Article: ] |
81. | Udkoff J, Waldman A, Ahluwalia J, Borok J, Eichenfield LF. Current and emerging topical therapies for atopic dermatitis. Clin Dermatol. 2017;35:375-382. [PubMed] [DOI] [Cited in This Article: ] |
82. | Brunner PM, Leung DYM, Guttman-Yassky E. Immunologic, microbial, and epithelial interactions in atopic dermatitis. Ann Allergy Asthma Immunol. 2018;120:34-41. [PubMed] [DOI] [Cited in This Article: ] |
83. | Rather IA, Bajpai VK, Kumar S, Lim J, Paek WK, Park YH. Probiotics and Atopic Dermatitis: An Overview. Front Microbiol. 2016;7:507. [PubMed] [DOI] [Cited in This Article: ] |
84. | Abrahamsson TR, Jakobsson HE, Andersson AF, Björkstén B, Engstrand L, Jenmalm MC. Low diversity of the gut microbiota in infants with atopic eczema. J Allergy Clin Immunol. 2012;129:434-440, 440.e1. [PubMed] [DOI] [Cited in This Article: ] |
85. | Kim H, Kim HR, Kim NR, Jeong BJ, Lee JS, Jang S, Chung DK. Oral administration of Lactobacillus plantarum lysates attenuates the development of atopic dermatitis lesions in mouse models. J Microbiol. 2015;53:47-52. [PubMed] [DOI] [Cited in This Article: ] |
86. | Kim JH, Kim K, Kim W. Gut microbiota restoration through fecal microbiota transplantation: a new atopic dermatitis therapy. Exp Mol Med. 2021;53:907-916. [PubMed] [DOI] [Cited in This Article: ] |
87. | Jiang X, Liu Z, Ma Y, Miao L, Zhao K, Wang D, Wang M, Ruan H, Xu F, Zhou Q, Xu S. Fecal microbiota transplantation affects the recovery of AD-skin lesions and enhances gut microbiota homeostasis. Int Immunopharmacol. 2023;118:110005. [PubMed] [DOI] [Cited in This Article: ] |
88. | Mashiah J, Karady T, Fliss-Isakov N, Sprecher E, Slodownik D, Artzi O, Samuelov L, Ellenbogen E, Godneva A, Segal E, Maharshak N. Clinical efficacy of fecal microbial transplantation treatment in adults with moderate-to-severe atopic dermatitis. Immun Inflamm Dis. 2022;10:e570. [PubMed] [DOI] [Cited in This Article: ] |
89. | Zhang Y, Lan F, Zhang L. Update on pathomechanisms and treatments in allergic rhinitis. Allergy. 2022;77:3309-3319. [PubMed] [DOI] [Cited in This Article: ] |
90. | Passali D, Cingi C, Staffa P, Passali F, Muluk NB, Bellussi ML. The International Study of the Allergic Rhinitis Survey: outcomes from 4 geographical regions. Asia Pac Allergy. 2018;8:e7. [PubMed] [DOI] [Cited in This Article: ] |
91. | Dong L, Tang Y, Wen S, He Y, Li F, Deng Y, Tao Z. Fecal Microbiota Transplantation Alleviates Allergic Rhinitis via CD4(+) T Cell Modulation Through Gut Microbiota Restoration. Inflammation. 2024;47:1278-1297. [PubMed] [DOI] [Cited in This Article: ] |
92. | Mahajan R, Midha V, Singh A, Mehta V, Gupta Y, Kaur K, Sudhakar R, Singh Pannu A, Singh D, Sood A. Incidental benefits after fecal microbiota transplant for ulcerative colitis. Intest Res. 2020;18:337-340. [PubMed] [DOI] [Cited in This Article: ] |
93. | Accordini S, Corsico AG, Braggion M, Gerbase MW, Gislason D, Gulsvik A, Heinrich J, Janson C, Jarvis D, Jõgi R, Pin I, Schoefer Y, Bugiani M, Cazzoletti L, Cerveri I, Marcon A, de Marco R. The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol. 2013;160:93-101. [PubMed] [DOI] [Cited in This Article: ] |
94. | Shapiro SD, Owen CA. ADAM-33 surfaces as an asthma gene. N Engl J Med. 2002;347:936-938. [PubMed] [DOI] [Cited in This Article: ] |
95. | Ober C. HLA-G: an asthma gene on chromosome 6p. Immunol Allergy Clin North Am. 2005;25:669-679. [PubMed] [DOI] [Cited in This Article: ] |
96. | Huang YJ, Boushey HA. The microbiome in asthma. J Allergy Clin Immunol. 2015;135:25-30. [PubMed] [DOI] [Cited in This Article: ] |
97. | Frati F, Salvatori C, Incorvaia C, Bellucci A, Di Cara G, Marcucci F, Esposito S. The Role of the Microbiome in Asthma: The Gut⁻Lung Axis. Int J Mol Sci. 2018;20. [PubMed] [DOI] [Cited in This Article: ] |
98. | Kang Y, Cai Y. Future prospect of faecal microbiota transplantation as a potential therapy in asthma. Allergol Immunopathol (Madr). 2018;46:307-309. [PubMed] [DOI] [Cited in This Article: ] |